Action ELYM ELIEM THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Eliem Therapeutics, Inc.

Actions

ELYM

US28658R1068

Temps réel estimé Cboe BZX
Autres places de cotation
 19:06:44 10/06/2024 		Varia. 5j. Varia. 1 janv.
8,565 USD -3,55 % Graphique intraday de Eliem Therapeutics, Inc. +3,12 % +218,52 %
15/05 Eliem Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI
11/04 Mise à jour sectorielle : Les actions du secteur de la santé en baisse en fin d'après-midi MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Eliem Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the Firm
Sector Update: Health Care Stocks Softer Late Afternoon
Top Midday Gainers
Sector Update: Health Care Stocks Decline Thursday Afternoon
Eliem Therapeutics to Acquire Tenet Medicines; Launching Private Placement -- Eliem Shares Surge
ELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to Shareholders
Top Premarket Gainers
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
Eliem Therapeutics, Inc. and Tenet Medicines, Inc. Announces Management and Organization Changes
Eliem Therapeutics, Inc. entered into a definitive acquisition agreement to acquire Tenet Medicines, Inc.
Eliem Therapeutics, Inc. announced that it expects to receive $119.955003 million in funding from RA Capital Management, L.P., Deep Track Capital, LP
Eliem Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Harpoon Therapeutics Appoints Chief Legal Officer, Chief People Officer
Eliem Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Eliem Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Eliem Therapeutics Drops Kv7 Program, Explores Strategic Alternatives
Eliem Therapeutics Plans to Explore Strategic Alternatives
Eliem Therapeutics Announces Plans to Explore Strategic Alternatives
Eliem Therapeutics Announces Plans to Explore Strategic Alternatives
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ELYM
  4. Actualités Eliem Therapeutics, Inc.
  5. Autres langues